Paragon Care's profit warning costs it a bull. Paragon Care now expects FY26 revenues of A$3.7 billion and Ebitda of A$95 million-A$100 million. That forecast includes a three-month month contribution from Haju Medical. Bell Potter notes Paragon Care's prior guidance of A$97 million-A$107 million excluded Haju Medical. "We estimate across the board inflationary pressures in the core Australian business have ripped up to A$4 million in earnings out with little to no means to pass on these costs to customers in the short term," analyst John Hester says. His FY26 and FY27 EPS forecasts fall by 10% and 18%, respectively. Bell Potter downgrades Paragon Care to hold, from buy, and cuts its price target by more than 40% to A$0.17/share. Paragon Care ended Monday at A$0.16. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

June 01, 2026 19:06 ET (23:06 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.